Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 18/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 18/20 | 0.52 |
| ▸ | KCNE1 | P15382 | 14/20 | 0.52 |
| ▸ | KCNQ1 | P51787 | 14/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455155 | 0.86 | MEN1 (0.40) | KCNQ3KCNQ2KCNE1KCNQ1RAB9A | |
| SCHEMBL5462336 | 0.81 | RAB9A (0.53) | RAB9ASMN1; SMN2 | |
| SCHEMBL6199317 | 0.79 | KCNQ3 (0.72) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5469832 | 0.78 | LMNA (0.60) | RAB9ASMN1; SMN2 | |
| SCHEMBL14885954 | 0.78 | P2RX1 (0.70) | KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL5463888 | 0.78 | PTGS1 (0.56) | RAB9A | |
| SCHEMBL14363248 | 0.76 | RAB9A (0.57) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5468300 | 0.76 | SNCA (0.56) | RAB9A | |
| SCHEMBL5462663 | 0.74 | MEN1 (0.47) | RAB9ASMN1; SMN2 | |
| SCHEMBL5464092 | 0.74 | TOP1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | KCNQ3 4820/4885KCNQ2 4674/4885KCNE1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.